Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Endocrinol Invest ; 47(4): 857-864, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-37752372

RESUMO

PURPOSE: To characterize patients with APS and to propose a new approach for their follow-up. Query ID="Q1" Text="Please check the given names and familynames." METHODS: Monocentric observational retrospective study enrolling patients referred to the Outpatients clinic of the Units of Endocrinology, Diabetology, Gastroenterology, Rheumatology and Clinical Immunology of our Hospital for Autoimmune diseases. RESULTS: Among 9852 patients, 1174 (11.9%) [869 (73.9%) female] were diagnosed with APS. In 254 subjects, the diagnosis was made at first clinical evaluation (Group 1), all the other patients were diagnosed with a mean latency of 11.3 ± 10.6 years (Group 2). Group 1 and 2 were comparable for age at diagnosis (35.7 ± 16.3 vs. 40.4 ± 16.6 yrs, p = .698), but different in male/female ratio (81/173 vs 226/696, p = .019). In Group 2, 50% of patients developed the syndrome within 8 years of follow-up. A significant difference was found after subdividing the first clinical manifestation into the different outpatient clinic to which they referred (8.7 ± 8.0 vs. 13.4 ± 11.6 vs. 19.8 ± 8.7 vs. 7.4 ± 8.1 for endocrine, diabetic, rheumatologic, and gastroenterological diseases, respectively, p < .001). CONCLUSIONS: We described a large series of patients affected by APS according to splitters and lumpers. We propose a flowchart tailored for each specialist outpatient clinic taking care of the patients. Finally, we recommend regular reproductive system assessment due to the non-negligible risk of developing premature ovarian failure.


Assuntos
Doenças Autoimunes , Endocrinologia , Poliendocrinopatias Autoimunes , Insuficiência Ovariana Primária , Humanos , Feminino , Masculino , Estudos Retrospectivos , Poliendocrinopatias Autoimunes/diagnóstico
2.
Water Sci Technol ; 77(1-2): 409-416, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29377825

RESUMO

Many emerging contaminants pass through conventional wastewater treatment plants, contaminating surface and drinking water. The implementation of advanced oxidation processes in existing plants for emerging contaminant remediation is one of the challenges for the enhancement of water quality in the industrialised countries. This paper reports on the production of a TiO2 nano-layer on quartz wool in a relevant amount, its characterisation by X-ray diffraction and scanning electron microscopy, and its use as a photocatalyst under ultraviolet radiation for the simultaneous mineralisation of five emerging organic contaminants (benzophenone-3, benzophenone-4, carbamazepine, diclofenac, and triton X-100) dissolved in deionised water and tap water. This treatment was compared with direct ultraviolet photolysis and with photocatalytic degradation on commercial TiO2 micropearls. The disappearance of every pollutant was measured by high performance liquid chromatography and mineralisation was assessed by the determination of total organic carbon. After 4 hours of treatment with the TiO2 nano-coated quartz wool, the mineralisation exceeds 90% in deionised water and is about 70% in tap water. This catalyst was reused for seven cycles without significant efficiency loss.


Assuntos
Nanopartículas/química , Quartzo/química , Titânio/química , Raios Ultravioleta , Poluentes Químicos da Água/análise , Purificação da Água/métodos , Catálise , Oxirredução , Fotólise , Propriedades de Superfície , Águas Residuárias/química , Poluentes Químicos da Água/química , Poluentes Químicos da Água/efeitos da radiação , Qualidade da Água
3.
J Chemother ; 16 Suppl 5: 23-5, 2004 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-15675471

RESUMO

The management of intraperitoneal tumors, especially when confined to the peritoneal cavity and/or associated with malignant ascites, requires the use of intraperitoneal (i.p.) cisplatin-based chemotherapy. This therapeutic approach, enabling high concentrations of drug and long duration of tumor tissue exposure, while generating a systemic exposure similar to that obtained with intravenous (i.v.) infusion, significantly improves therapeutic ratio. Nowadays, as feasibility issues are easy to overcome, intraperitoneal chemotherapy provides a safe, effective treatment for the management of peritoneal disease, particularly ovarian carcinoma. In this paper we review pharmacological issues of intraperitoneal cisplatin-based chemotherapy in order to provide a ready to use information collection for clinical practice and ongoing research.


Assuntos
Cisplatino/administração & dosagem , Neoplasias Peritoneais/tratamento farmacológico , Cisplatino/farmacocinética , Humanos , Hipertermia Induzida , Injeções Intraperitoneais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA